Reaction
Abdominal Neoplasm reporting signals
As of the last recalculation, Abdominal Neoplasm appears in 879 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 30.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 38 | 30.7 | 30.7 |
| Niraparib | 27 | 29.7 | 29.7 |
| Polatuzumab Vedotin | 10 | 24.5 | 24.6 |
| Lanreotide Acetate | 7 | 21.3 | 21.3 |
| Obinutuzumab | 13 | 19.0 | 19.0 |
| Rucaparib | 7 | 18.9 | 18.9 |
| Bendamustine Hcl | 12 | 18.6 | 18.6 |
| Doxorubicin Hydrochloride | 19 | 14.1 | 14.1 |
| Imatinib Mesylate | 15 | 12.9 | 12.9 |
| Vincristine Sulfate | 15 | 12.3 | 12.3 |
| Avapritinib | 4 | 7.9 | 7.9 |
| Pazopanib Hydrochloride | 8 | 7.1 | 7.1 |
| Vemurafenib | 3 | 5.9 | 5.9 |